Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)

A Phase IIa Dose-Refinement Study of the Safety and Immunogenicity of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine in Healthy Adults

This study will test the safety and immunogenicity of an investigational Human Immunodeficiency Virus (HIV) vaccine. Immunogenicity will be measured by evaluating the immune response to several different dose levels.

Inclusion Criteria:

• Demonstrates good general health
• Human Immunodeficiency Virus (HIV), Hepatitis B surface Antigen (HBsAg), and Hepatitis C (HCV) seronegative
• Low risk of acquiring HIV infection
• ALT lab value within normal range

Exclusion Criteria:

• Previously received an investigational HIV vaccine
• Has a known or suspected impairment of immunologic function
• Has a clinically significant chronic medical condition that is considered progressive
• Has a major psychiatric illness
• Has any history of malignancy, with the exception of basal cell or squamous cell skin cancer
• Weighs less than 105 lbs.
• Has a recent (within two years) history of chronic alcohol abuse
• Has a contraindication to intramuscular (IM) injection, such as anticoagulant therapy or thrombocytopenia
• Female is pregnant or breast feeding, or expecting to conceive or donate eggs during the study
• Male subject is planning to impregnate or provide sperm donation during the study